COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,637 Articles (22,913 medRxiv, 8,724 bioRxiv)

Most recent first Previous |  Page 1948: Articles 19471-19480  | Next

Combining science and social engagement againstCovid-19 in a Brazilian Slum
Evangelista, H., Goncalves, S. J., Sodre, E. D., Nogueira, J., Barbosa, R. G., Magalhaes, N., dos Santos, A. M. G., Godoi, R. H. M., Amaral, C., Cataldo, M., de Oliveira, D. A. J., Porto, L. C.
10.1101/2021.01.06.21249243 — Posted: 2021-01-09
A Multiple Linear Regression Analysis of Rural-Urban COVID-19 Risk Disparities in Texas
Luo, A. K., Zhong, S., Sun, C., Wang, J., White, A.
10.1101/2021.01.05.20248921 — Posted: 2021-01-08
Inflight Transmission of COVID-19 Based on Aerosol Dispersion Data
Wang, Z., Galea, E. R., Grandison, A. J., Ewer, J., Jia, F.
10.1101/2021.01.08.21249439 — Posted: 2021-01-08 Discussion: Onsite
Ad26.COV2.S-elicited immunity protects against G614 spike variant SARS-CoV-2 infection in Syrian hamsters and does not enhance respiratory disease in challenged animals with breakthrough infection after sub-optimal vaccine dosing
van der Lubbe, J. E. M., Rosendahl Huber, S. K., Vijayan, A., Dekking, L., van Huizen, E., Vreugdenhil, J., Choi, Y., Baert, M. R. M., Feddes-de Boer, K., Izquierdo Gil, A., van Heerden, M., Dalebout, T. J., Myeni, S. K., Kikkert, M., Snijder, E. J., de Waal, L., Stittelaar, K. J., Tolboom, J. T. B. M., Serroyen, J., Muchene, L., van der Fits, L., Rutten, L., Langedijk, J. P. M., Barouch, D. H., Schuitemaker, H., Zahn, R. C., Wegmann, F.
10.1101/2021.01.08.425915 — Posted: 2021-01-08
Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2
Nair, M. S., Huang, Y., Fidock, D. A., Polyak, S. J., Wagoner, J., Towler, M., Weathers, P.
10.1101/2021.01.08.425825 — Posted: 2021-01-08 Discussion: Onsite
Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naïve human antibody library
Bell, B. N., Powell, A. E., Rodriguez, C., Cochran, J. R., Kim, P. S.
10.1101/2021.01.07.425806 — Posted: 2021-01-08 Discussion: Onsite
Vimentin binds to SARS-CoV-2 spike protein and antibodies targeting extracellular vimentin block in vitro uptake of SARS-CoV-2 virus-like particles
Suprewicz, L., Swoger, M., Gupta, S., Piktel, E., Byfield, F. F., Iwamoto, D. V., Germann, D. A., Reszec, J., Marcinczyk, N., Janmey, P. A., Schwarz, J. M., Bucki, R., Patteson, A. E.
10.1101/2021.01.08.425793 — Posted: 2021-01-08 Discussion: Offsite
Fibrinolysis influences SARS-CoV-2 infection in ciliated cells
Hou, Y., Ding, Y., Nie, H., Ji, H.-L.
10.1101/2021.01.07.425801 — Posted: 2021-01-08
A two-phase stochastic dynamic model for COVID-19 mid-term policy recommendations in Greece: a pathway towards mass vaccination
Rachaniotis, N. P., Dasaklis, T. K., Fotopoulos, F., Tinios, P.
10.1101/2021.01.07.21249394 — Posted: 2021-01-08
Timeliness of U.S. mortality data releases during the COVID-19 pandemic: delays are associated with electronic death registration system and elevated weekly mortality
Rosenbaum, J. E., Stillo, M., Graves, N., Rivera, R.
10.1101/2021.01.07.21249401 — Posted: 2021-01-08

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).